
Feb 2 (Reuters) - Aquestive Therapeutics Inc AQST.O:
AQUESTIVE THERAPEUTICS ANNOUNCES FDA ISSUANCE OF COMPLETE RESPONSE LETTER FOR ANAPHYLM™
AQUESTIVE THERAPEUTICS INC - DEFICIENCIES LIMITED TO PACKAGING AND ADMINISTRATION
AQUESTIVE THERAPEUTICS INC - COMPANY EXPECTS TO RESUBMIT AS EARLY AS Q3 2026
AQUESTIVE THERAPEUTICS INC - PLANS TO SUBMIT IN CANADA AND EU BY END OF 2026
AQUESTIVE THERAPEUTICS INC: PLANS TO REQUEST RAPID REVIEW BY FDA
AQUESTIVE THERAPEUTICS INC - COMPANY ANTICIPATES ENDING 2026 WITH SIGNIFICANT CASH